J Clin Oncol 2005,23(25):5973–5982 PubMed 41 De Placido S, De La

J Clin Oncol 2005,23(25):5973–5982.PubMed 41. De Placido S, De Laurentiis M, De Lena M, Lorusso V, Paradiso A, D’Aprile M, Pistillucci G, Farris A, Sarobba MG, Palazzo S, Manzione L, Adamo V, Palmeri S, Ferraù F, Lauria R, Pagliarulo C, Petrella G, Limite G, Costanzo R, Bianco AR, GOCSI Cooperative Group:

A randomised factorial buy RG7420 trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive EVP4593 chemical structure breast cancer. Br J Cancer 2005,14(3):467–474. 42. Eiermann W, Graf E, Ataseven B, Conrad B, Hilfrich J, Massinger-Biebl H, Vescia S, Loibl S, von Minckwitz G, Schumacher M, Kaufmann M: Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) – The German Adjuvant Breast Cancer Group. Eur J Cancer 2010,46(1):84–94.PubMed 43. Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin

M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR: Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human learn more Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. J Clin Oncol 2011,29(29):3877–3884.PubMed 44. Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL: Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer. J Clin Oncol 2006,24(31):4956–4962.PubMed 45. Focan C, Beauduin M, Majois F, Canon JL, Cusumano G, Focan-Henrard D, Lobelle JP: High-dose

oral medroxyprogesterone acetate or tamoxifen PR-171 research buy as adjuvant hormone therapy for node-negative early-stage breast cancer: randomized trial with 7-year update. Clin Breast Cancer 2004,5(2):136–141.PubMed 46. Fountzilas GSG, Kouvatseas G, Polychronis A, Klouvas G, Samantas E, Zamboglou N, Kyriakou K, Adamou A, Pectasidis D, Ekonomopoulos T, Kalofonos HP, Bafaloukos D, Georgoulias V, Razis E, Koukouras D, Zombolas V, Kosmidis P, Skarlos D, Pavlidis N, Hellenic Cooperative Oncology Group: Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. Am J Clin Oncol 2004,27(1):57–67.PubMed 47.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>